Compare Cytokinetics Inc (CYTK) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs LyondellBasell Industries NV — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while LyondellBasell Industries NV trades at $58.61 (market cap $18.90B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 7.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LYB | |
|---|---|---|
Market Cap | $11.12B | $18.90B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $82.38 |
52-Week Low | $33.23 | $42.28 |
Enterprise Value | $11.59B | $30.52B |
Dividend Yield | — | 7.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
LyondellBasell (LYB) trades at $58.32, up 3.49% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported mixed earnings, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $50.5B in 2022 to $30.2B in 2025. Recent news highlights partnerships for sustainable packaging and upcoming Q2 2026 results. Despite negative net income margins and ROE, LYB maintains positive operating cash flow and a dividend payout.
LYB presents a cautious opportunity with analyst consensus leaning toward Buy (43.59%) and a $73.11 price target, suggesting 25% upside. Risks include persistent revenue declines, elevated debt, and industry headwinds, but cost-cutting and focus on high-margin polymers offer potential recovery. Investors should weigh the bullish technicals and analyst optimism against fundamental challenges in the chemical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
